Skip to main content
Have a personal or library account? Click to login
Current status and future prospects of drug eluting stents for restenosis / Sadašnjost i budućnost stentova za restenozu koji otpuštaju lijekove Cover

Current status and future prospects of drug eluting stents for restenosis / Sadašnjost i budućnost stentova za restenozu koji otpuštaju lijekove

Open Access
|Jan 2013

References

  1. 1. E. Sousa, P. Serruys and M. Costa, New frontiers in cardiology: drug-eluting stents: Part I,(2003) 2274-2279; DOI: 10.1161/01.CIR.0000069330.41022.90.
  2. 2. E. Edelman and C. Rogers, Pathobiologic responses to stenting,.(1998) 4E-6E; DOI: 10.1016/S0002-9149(98)00189-1.
  3. 3. P. Serruys, B. Strauss and H. Van Beusekom, Stenting of coronary arteries: has a modern Pandora’s Box been opened?.(1991) 143B-154B; DOI: 10.1016/0735-1097(91)90951-5.
  4. 4. M. Costa, D. Foley and P. Serruys,, in(Eds. E. Grech and D. Ramsdale), 2nd ed., Martin Dumitz, London 2002, pp. 279-294.
  5. 5. D. Whelan, H. Van Beusekom and W. Van der Giessen, Mechanisms of drug loading and release kinetics,(1998) 127-131.
  6. 6. W. Van der Giessen, A. Lincoff and R. Schwartz, Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries,(1996) 1690-1697; DOI: 10.1161/01.CIR.94.7.1690.
  7. 7. D. Drachman, E. Edelman and P. Seifert, Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months,.(2000) 2325-2332; DOI: 10.1016/S0735-1097(00)01020-2.
  8. 8. B. Ratner, The blood compatibility catastrophe,(1993) 283-287; DOI: 10.5897/AJPP11.107.
  9. 9. M. Lovich, C. Creel and K. Hong, Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel,.(2001) 1324-1335; DOI: 10.1002/JPS.1085.
  10. 10. R. Braun-Dullaeus, M. Mann and V. Dzau, Cell cycle progression: new therapeutic target for vascular proliferative disease,(1998) 82-89; DOI: 10.1161/01.CIR.98.1.82.
  11. 11. C. Morton Allison, D. Crossman and J. Gunn, The influence of physical stent parameters upon restenosis,.(2004) 196-205; DOI: 10.1016/J.PATBIO.2004.03.013.
  12. 12. C. Rogers, Optimal stent design for drug delivery,(2004) S9-S15.
  13. 13. K. Lau, A. Johan, U. Sigwart and J. Hung, A stent is not just a stent: stent construction and design do matter in its clinical performance,(2004) 305-312.
  14. 14. A. Colombo, G. Stankovic and J. W. Moses, Selection of coronary stents,.(2002) 1021-1033.
  15. 15. D. Stoeckel, C. Bonsignore and S. Duda, A survey of stent designs,(2002) 137-147.
  16. 16. L. Lim, Biocompatability of stent materials,(2004) 33-37.
  17. 17. J. Bier, P. Zalesky and S. Li, A new bioabsorbable intravascular stent: in vitro assessment of hemodynamic and morphometric characteristics,.(1992) 187-194.
  18. 18. B. Berk, J. Gordon and R. Alexander, Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty,.(1991) 111B-117B; DOI: 10.1016/0735-1097(91)90946-7.
  19. 19. C. Pepine, J. Hirshfeld and R. Macdonald, A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty,(1990) 1753-1761; DOI: 10.1161/01.CIR.81.6.1753.
  20. 20. I. De Scheerder, K. Wang and K. Wilczek, Local methylprednisolone inhibition of foreign body response to coated intracoronary stents,(1996) 161-166.
  21. 21. A. M. Lincoff, J. G. Furst and S. G. Ellis, Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model,(1997) 808-816; DOI: 10.1016/S0735-1097(96)00584-0.
  22. 22. D. Holmes, M. Savage and J. LaBlanche, Results of prevention of restenosis with tranilast and its outcomes (PRESTO) trial,(2002) 1243-1250. DOI: 10.1161/01.CIR.0000028335.31300DA.
  23. 23. A. Farb, M. John, E. Acampado, F. D. Kolodgie, M. F. Prescott and R. Virmani, Oral everolimus inhibits in-stent neointimal growth,(2002) 2379-2384; DOI: 10.1161/01.CIR.0000033973.06059.04.
  24. 24. P. B. Schiff and S. B. Horwitz, Taxol stabilizes microtubules in mouse fibroblast cells,(1980) 1561-1565.
  25. 25. P. W. Serruys, Long-term effects of angiopeptin treatment in coronary angioplasty: reduction of clinical events but not angiographic restenosis,(1995) 2759-2760.
  26. 26. R. K. Aggarwal, D. C. Ireland, M. A. Azrin, M. D. Ezekowitz, D. P. de Bono and A. H. Gershlick, Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody,(1996) 3311-3317; DOI: 10.1161/01.CIR.94.12.3311.
  27. 27. C. Li, W. J. Cantor, N. Nili, R. Robinson, L. Fenkell and Y. L. Tran, Arterial repair after stenting and the effects of GM6001, a matrix metalloproteinase inhibitor,(2002) 1852-1858; DOI: 10.1016/S0735-1097(02)01873-9.
  28. 28. C. Rogers, S. Parikh, P. Seifert and E. R. Edelman, Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair,(1996) 2909-2914; DOI: 10.1161/01.CIR.94.11.2909.
  29. 29. J. Aoki, P. W. Serruys, H. van Beusekom, A. T. Ong, E. P. McFadden and G. Sianos, Endothelial progenitor cell capture by stents coated with antibody against CD34: The healing-FIM (healthy endothelial accelerated lining inhibits neointimal growth-first in man) registry,(2005) 1574-1579.
  30. 30. D. J. Cohen, Economics of coronary restenosis: implications of drug-eluting stents, http://www.tctmd.com/show.aspx?id=58808; last access: April 22, 2012
  31. 31. P. W. Serruys, P. de Jaegere, F. Kiemeneij, C. Macaya, W. Rutsch, G. Heyndrickx, H. Emanuelsson, J. Marco, V. Legrand, P. Materne, J. Belardi, U. Sigwart, A. Colombo, J. J. Gay, P. Henvel, J. Delcan and M. Morel, A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease,(1994) 489-495; DOI: 10.10.1056/NEJM199408253310801.
  32. 32. H. Tamai, K. Igaki, E. Kyo, K. Kosuga, A. Kawashima, S. Matsui, H. Komori, T. Tsuji, S. Motohara and H. Uehata, Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans,(2000) 399-404; DOI: 10.1161/01.CIR.102.4.399.
  33. 33. J. A. Ormiston, P. W. Serruys, E. Regar, D. Dudek, L. Thuesen, M. W. Webster, Y. Onuma, H. M. Garcia-Garcia, R. McGreevy and S. Veldhof, A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial,(2008) 899-907; DOI: 10.1016/S0140-6736(08)60415-8.
  34. 34. J. A. Ormiston and P. W. Serruys, Bioabsorbable coronary stents,(2009) 255-260; DOI: 10.1161/CIRCINTERVENTIONS.109.859173.
  35. 35. S. Ramcharitar and P. W. Serruys, Fully biodegradable coronary stents: progress to date,(2008) 305-314.
  36. 36. R. Erbel, C. Di Mario, J. Bartunek, J. Bonnier, B. de Bruyne, F. R. Eberli, P. Erne, M. Haude, B. Heublein, M. Horrigan, C. Ilsley, D. Bose, J. Koolen, T. F. Luscher, N. Weissman and R. Waksman, Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial,(2007) 1869-1875; DOI: 10.1016/S0140-6736(07)60853-8.
  37. 37. N. Tada, R. Virmani, G. Grant, L. Bartlett, A. Black, C. Clavijo, U. Christians, R. Betts, D. Savage, S. H. Su, J. Shulze and S. Kar, Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model,(2010) 174-183; DOI: 10.1161/CIRCINTERVENTIONS.109.87522.
  38. 38. J. R. Costa, Jr., A. Abizaid, R. Costa, F. Feres, L. F. Tanajura, G. Maldonado, R. Staico, D. Siqueira, A. G. Sousa, R. Bonan and J. E. Sousa, 1-Year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial,(2009) 422-427; DOI: 10.1016/j.jcin.2009.02.009.
  39. 39. J. Aoki, P. W. Serruys, H. van Beusekom, A. T. L. Ong, E. P. McFadden and G. Sianos, Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry,(2005) 1574-1579; DOI: 10.1016/j.jacc.2005.01.048.
  40. 40. H. J. Duckers, S. Silber, R. D. Winter, P. D. Heijer, B. Rensing and M. Rau, Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent,(2007) 67-75.
  41. 41. M. Co, E. Tay, C. H. Lee, K. K Poh, A. Low and J. Lim, Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate- to long-term clinical follow-up,(2008) 128-132; DOI: 10.1016/j.ahj.2007.08.031.
  42. 42. A. Abizaid and J. R. Costa, Jr., New drug-eluting stents: An overview on biodegradable and polymer-free next-generation stent system,(2010) 384-393; DOI: 10.1161/CIRCINTERVENTIONS.109.891192.
  43. 43. C. Lovadahl, J. Thyber and A. Hultgardh-Nilsson, The synthetic metalloproteinase inhibitor batimastat suppresses injury induced phosphorylation of MAP kinase ERK/ERK2 and phenotypic modification of arterial smooth muscle cells in vitro,(2000) 345-354; DOI: 10.1159/000025750.
  44. 44. P. W. Serruys, S. Garg, A. Abizaid, J. Ormiston, S. Windecker, S. Verheye, C. Dubois, J. Stewart, K. E. Hauptmann, J. Schofer, K. Stangl, B. Witzenbichler, M. Wiemer, E. Barbato, T. de Vries, A. M. den Drijver, H. Otake, L. Meredith, S. Toyloy and P. Fitzgerald, A randomised comparison of novolimus-eluting and zotarolimus eluting coronary stents: 9-month follow-up results of the EXCELLA II study,(2010) 195-205.
DOI: https://doi.org/10.2478/v10007-012-0036-8 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English, Croatian, Slovenian
Page range: 473 - 496
Published on: Jan 15, 2013
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Related subjects:

© 2013 Maulik J. Patel, Sanjay S. Patel, Nidhi S. Patel, Natvarlal M. Patel, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.